Sanara MedTech Q2 Results: Sales Rise 9% YoY, EPS Misses Estimate

Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).

Original reporting
Published Aug 11, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sanara MedTech Q2 Results: Sales Rise 9% YoY, EPS Misses Estimate — source image
Decision brief

The 30-second read

$SMTIBearishMed
01

Why it matters

Traders should weigh two catalysts: (1) the quantified earnings miss that can reset near-term expectations for margins, and (2) deal uncertainty from investigations that can affect deal probability and shareholder acceptance dynamics.

02

Market read

SMTI has both an earnings disappointment and fresh deal-related legal overhang, which can drive volatility and reprice deal-risk and margin expectations.

03

What to watch

Deal litigation may not block closing; the offer is heavily cash-weighted ($33 cash vs $35 total), which can reduce downside for SMTI holders if the process ultimately clears.

Relevance 8/10Novelty 7/10Timing: after-hours following Q2 results and alongside fresh acquisition-investigation headlines

Background

Sanara MedTech reported Q2 results showing revenue growth but continued losses, while a proposed acquisition by MiMedx is facing multiple shareholder-law-firm investigations over alleged fiduciary duty and disclosure issues.

Company-level read

Ticker impact

$SMTIBearishMedium confidence
Context

Sanara MedTech reported Q2 EPS of -$0.05, missing the $0.02 estimate, while sales rose to $28.137M.

Expected impact

Choppy-to-lower bias until investors see margin stabilization and deal terms clear legal scrutiny.

Evidence & confidence

The article discloses a quantified earnings miss plus multiple law-firm investigations into the MiMedx acquisition, both of which can pressure sentiment and deal certainty.

$MDXGNeutralLow confidence
Context

MiMedx is the acquirer in the proposed Sanara MedTech deal, with the offer including 0.4735 MDXG shares per SMTI share.

Expected impact

Limited directional edge from this article alone, but deal-related headlines can move the stock around legal and closing-probability updates.

Evidence & confidence

The text focuses on SMTI’s earnings and legal challenges; it provides deal mechanics and MDXG’s average price used for valuation, but no new MDXG-specific operational update.

Market effects

Could reinforce investor skepticism toward small/mid-cap medtech profitability conversion, especially when growth does not translate to EPS.

Primarily US small/mid-cap sentiment, with no explicit regional macro linkage in the text.

Low, as the article is company-specific and deal-focused with no cross-border regulatory or supply-chain shock described.

Counterpoint

The EPS loss narrowed sharply year over year (-$0.23 to -$0.05) and revenue grew, suggesting the miss may be temporary rather than a structural deterioration.

Key entities

  • Sanara MedTech Inc.

    NASDAQ-listed medtech company reporting Q2 EPS -$0.05 and revenue $28.137M, and subject of an acquisition investigation.

  • MiMedx Group, Inc.

    NASDAQ-listed acquirer in the proposed transaction, whose stock is part of the consideration structure.

  • Kahn Swick & Foti, LLC

    Launched an investigation into the proposed Sanara MedTech acquisition fairness and board conduct.

  • Monteverde & Associates PC

    Previously raised scrutiny of the transaction process and alleged shareholder harm.

  • Ademi LLP

    Alleged the board failed to secure the best price and ran a conflict-prone process.

Related articles

$SMTIMed

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

$MDXGMed

MiMedx Group Inc (MDXG) (Q3 2026) Earnings Call Highlights: Revenue Jumps 36%

MiMedx Group Inc (MDXG) reported a 36% revenue jump in Q3 2026. CFO Danilo D'Alessandro expects gradual reduction in cash burn over the next four to six quarters. CEO Joe Burnett highlighted growth opportunities in spine laser therapy, with estimated revenue of $13,000 to $20,000 per procedure. The company aims for mid-teens growth in 2027, with guidance expected in January. MDXG also discussed investments in robotics and focused ultrasound, and the status of the UniQure AMT-130 BLA submission.

$MDXGMed

MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.

$MDXGHighAI 8/10

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group (MDXG) reported Q3 earnings with gross profit of $50M, down from $95M YoY, and a GAAP net loss of $9M. Wound care volume rose 20% YoY, but margins declined due to pricing and product mix. The company expects 2027 conditions to persist and anticipates modest EBITDA growth in Q4. MiMedx is acquiring Sanara MedTech, facing FTC review, aiming for $400M revenue and 20% EBITDA margin post-merger. Legal and product updates include a $25M settlement and progress on 510(k) submissions.

$MDXGMed

MiMedx: Q3 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q3 loss of $8.7 million, or 6 cents per share, with adjusted losses of 1 cent per share. Revenue was $62.3 million. The company expects full-year revenue between $250 million and $260 million, according to its earnings release.